Page 2 - Saturnv Capital Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Saturnv capital management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Saturnv Capital Management Today - Breaking & Trending Today

Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Drop in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,030,000 shares, a decrease of 18.3% from the July 15th total of 1,260,000 shares. Based on an average daily volume of 256,800 shares, the short-interest ratio […] ....

United States , Astria Therapeutics Inc , Affinity Asset Advisors , Saturnv Capital Management , Mirabella Financial Services , Astria Therapeutics Company Profile , Fairmount Funds Management , Astria Therapeutics , Get Free Report , Funds Management , Global Management , Asset Advisors , Astria Therapeutics Daily , Nasdaq Atxs ,

Chinook Therapeutics (NASDAQ:KDNY) Sees Large Volume Increase

Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Free Report) saw an uptick in trading volume on Wednesday . 2,530,496 shares traded hands during trading, an increase of 145% from the previous session’s volume of 1,032,166 shares.The stock last traded at $40.29 and had previously closed at $40.29. Wall Street Analyst Weigh In Several brokerages […] ....

William Mariner Greenman , Andrew James King , William Blair , Chinook Therapeutics Inc , Wells Fargo Company , Millennium Management , Saturnv Capital Management , Franklin Resources Inc , Chinook Therapeutics Company Profile , Securities Exchange Commission , Chinook Therapeutics , Get Free Report , Bloom Burton , Therapeutics Trading Down , Exchange Commission , Director William Mariner Greenman , Street Corp , Chinook Therapeutics Daily , Nasdaq Kdny ,

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insider Sells $248,591.07 in Stock

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) insider Charles Mcwherter sold 21,749 shares of the stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $11.43, for a total value of $248,591.07. Following the completion of the sale, the insider now owns 15,000 shares in the company, […] ....

Charles Mcwherter , William Blair , Securities Exchange Commission , Perceptive Advisors , Franklin Resources Inc , Cantor Fitzgerald , Cymabay Therapeutics Inc , Bain Capital Life Sciences Investors , Saturnv Capital Management , Cymabay Therapeutics , Get Free Report , Exchange Commission , Bay Therapeutics , Capital Life Sciences Investors , Cymabay Therapeutics Daily , Nasdaq Cbay , Insider Trading , Nsider Trades ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month price objective among […] ....

United States , Fady Ibraham Malik , Roberti Blum , Chilton Capital Management , Jpmorgan Chase Co , Prelude Capital Management , Saturnv Capital Management , Cantor Fitzgerald , Securities Exchange Commission , Cytokinetics Company Profile , Cytokinetics Incorporated , Free Report , Exchange Commission , Ibraham Malik , Capital Management , Cytokinetics Daily , Nasdaq Cytk ,

KalVista Pharmaceuticals (KALV) Scheduled to Post Earnings on Wednesday

KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) is set to release its earnings data on Wednesday, July 5th. KalVista Pharmaceuticals Price Performance Shares of NASDAQ:KALV opened at $9.04 on Tuesday. The firm has a market capitalization of $308.90 million, a PE ratio of -2.53 and a beta of 1.06. The business has a 50-day moving average […] ....

Thomas Andrew Crockett , News Ratings For Kalvista Pharmaceuticals Daily , Securities Exchange Commission , Kalvista Pharmaceuticals Inc , Kalvista Pharmaceuticals , Vanguard Group Inc , Earnings History For Kalvista Pharmaceuticals , Morgan Stanley , Needham Company , Kalvista Pharmaceuticals Price Performance , Blackrock Inc , Saturnv Capital Management , Cantor Fitzgerald , Free Report , Vista Pharmaceuticals , Andrew Crockett , Exchange Commission , Christopher Yea , Kalvista Pharmaceuticals Daily ,